E-Prescribing Vendors Talk Back


By Neil Versel, contributing editor

November 4, 2008 | A month ago, acting Centers for Medicare and Medicaid Services (CMS) administrator Kerry Weems said that physicians can no longer use cost as an excuse for not switching to electronic prescribing. “The business case is turned around,” Weems said citing the affordability of the technology and reasonably small workflow changes it requires.

If the vendor booths at the recent Medical Group Management Association (MGMA) annual meeting were any indication, the promise of 2 percent Medicare bonuses for e-prescribing has captured the attention of doctors and spurred all kinds of interest in health-IT.

“It’s created a sense of urgency that hasn’t been there before,” says Greg White, executive director of health care banking and payer solutions for RelayHealth, a McKesson subsidiary that offers e-prescribing software and services.

Doug Hart, RelayHealth’s senior director of marketing, says e-prescribing gives medical practices more of an advantage than before because it can produce a much faster return on investment than a full electronic medical record, something that is particularly important in this tough economy. Hart reports “lots of interest” in the company’s offering specifically because of the Medicare incentives, but also is seeing inquiries about secure messaging with patients, automation of referrals, appointment scheduling, and the population of personal health records through the RelayHealth user portal.

Starting Jan. 1, physicians can earn an extra 2 percent on top of regular Medicare Part B fees for “successful” e-prescribing. (CMS promises a definition of “successful” as well as detailed rules for the program by Nov. 15.) The bonus falls to 1 percent in 2011, then 0.5 percent in 2013. Meanwhile, those who have not made the switch by 2012 will be subject to penalties. (See “CMS Focuses on E-Prescribing.”)

Since Congress authorized the bonuses with the passage of the Medicare Improvements for Patients and Providers Act in mid-July, Allscripts-Misys Healthcare Solutions, the product of the recently completed merger of ambulatory systems vendors Allscripts Healthcare Solutions and Misys Healthcare Systems, has seen 15 percent monthly growth in the number of e-prescribing customers.

Even though Allscripts offers a free, standalone e-prescribing system through its National ePrescribing Patient Safety Initiative, the Chicago-based company had a lot of interest in complete EMRs from MGMA attendees who saw e-prescribing demos. “It leads to questions about what’s the pathway from e-prescribing to a full EMR,” says Allscripts president and chief operating officer Lee Shapiro.

Similarly, Sage Software Healthcare spokeswoman Lynne Durham says e-prescribing came up in the first 10 conversations she had at the meeting, though much of the interest was in e-prescribing as part of a broader EMR. Sage customers are writing more than 700,000 electronic prescriptions a month, and the majority are from users of the full EMR, Durham reports. “We haven’t seen a lot of rush for the standalone product,” she says.

Eclipsys, a hospital systems vendor that acquired ambulatory IT company MediNotes in October, has had a similar experience. “We’re seeing less interest in standalone e-prescribing than perhaps the buzz was six months ago,” says Thomas R. Cooke, Eclipsys senior vice president of business development.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .